MRI screening for chronic anticoagulation in atrial fibrillation

Frontiers in Neurology

Volumn 4 OCT, Issue , 2013, Pages

  Fisher, Mark ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Hemorrhage; Microbleeds; MRI; Stroke

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; RIVAROXABAN; WARFARIN;

AGING; ALGORITHM; ANTICOAGULATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG UTILIZATION; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; IMAGE QUALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICIAN ATTITUDE; PRESCRIPTION; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; WHITE MATTER;

EID: 84885340491     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2013.00137     Document Type: Short Survey

References (50)

1. Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective (1992 to 2002). Stroke (2006) 37:1969-74.
2. ShroffGR, Solid CA, Herzog CA. Temporal trends in ischemic stroke and anticoagulation therapy among Medicare patients with atrial fibrillation: a 15-year perspective (1992-2007). JAMA Intern Med (2013) 173:159-60. doi: 10.1001/jamainternmed.2013.1579.
3. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med (2010) 123:638-45. doi:10.1016/j.amjmed.2009.11.025.
4. Sandhu RK, Bakal JA, Ezekowitz JA, McAlister FA. Risk stratification schemes, anticoagulation use and outcomes: the risk-treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. Heart (2011) 97:2046-50. doi:10.1136/heartjnl-2011-300901.
5. Ewen E, Zhang Z, Simon TA, Kolm P, Liu X, Weintraub WS. Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices. Vasc Health Risk Manag (2012) 8:587-98. doi:10.2147/VHRM.S34280.
6. Witt DM, Delate T, Garcia DA, Clark NP, Hylek EM, Ageno W, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med (2012) 172:1484-91. doi:10.1001/archinternmed.2012.4261.
7. Ghaswalla PK, Harpe SE, Slattum PW. Warfarin use in nursing home residents: results from the 2004 national nursing home survey. Am J Geriatr Pharmacother (2012) 10:25-36. doi:10.1016/j.amjopharm.2011.12.001.
8. Zimetbaum PJ, Thosani A, Yu HT, Xiong Y, Lin J, Kothawala P, et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med (2010) 123:446-53. doi:10.1016/j.amjmed.2009.11.015.
9. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, et al. Stroke prevention in atrial fibrillation investigators. Lessons from the stroke prevention in atrial fibrillation trials. Ann Intern Med (2003) 138:831-8. doi:10.7326/0003-4819-138-10-200305200-00011.
10. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med (1994) 154:1449-57. doi:10.1001/archinte.1994.00420130036007.
11. Thygesen SK, Frost L, Eagle KA, Johnsen SP. Atrial fibrillation in patients with ischemic stroke: a population-based study. Clin Epidemiol (2009) 1:55-65.
12. Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing (2011) 40:675-83. doi:10.1093/ageing/afr097.
13. Gross CP, Vogel EW, Dhond AJ, Marple CB, Edwards RA, Hauch O, et al. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther (2003) 25:1750-64. doi:10.1016/S0149-2918(03)80167-4.
14. Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Semin Neurol (2010) 30:565-72. doi:10.1055/s-0030-1268866.
15. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation (2007) 115(21):2689-96. doi:10.1161/CIRCULATIONAHA.106.653048.
16. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 361:1139-51. doi:10.1056/NEJMoa0905561.
17. Patel MR, Mahaffey KW, Garg J. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 365:883-91. doi:10.1056/NEJMoa1009638.
18. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (2011) 4:14-21. doi:10.1161/CIRCOUTCOMES.110.958108.
19. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J (2013) 34:489b-98b. doi:10.1093/eurheartj/ehs408.
20. Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J (2013) 34:1041-9. doi:10.1093/eurheartj/ehs435.
21. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the national registry of atrial fibrillation (NRAF). Am Heart J (2006) 151:713-9. doi:10.1016/j.ahj.2005.04.017.
22. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (anticoagulation and risk factors in atrial fibrillation) study. J Am Coll Cardiol (2011) 58:395-401. doi:10.1016/j.jacc.2011.03.031.
23. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol (2012) 60:861-7. doi:10.1016/j.jacc.2012.06.019.
24. Poels MM, Vernooij MW, Ikram MA, Hofman A, Krestin GP, van der Lugt A, et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke (2010) 41(10 Suppl):S103-6. doi:10.1161/STROKEAHA.110.595181.
25. Fazekas F, Kleinert R, Roob G, Kleinert G, Kapeller P, Schmidt R, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol (1999) 20:637-42.
26. Fisher M, French S, Ji P, Kim RC. Cerebral microbleeds in the elderly: a pathological analysis. Stroke (2010) 41:2782-5. doi:10.1161/STROKEAHA.110.593657.
27. Koennecke HC. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology (2006) 66:165-71. doi:10.1212/01.wnl.0000194266.55694.1e.
28. Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CL, Edinburgh Stroke Study Groupet al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke (2010) 41:1222-8. doi:10.1161/STROKEAHA.109.572594.
29. Lee SH, Ryu WS, Roh JK. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. Neurology (2009) 72:171-6. doi:10.1212/01.wnl.0000339060.11702.dd.
30. Soo YOY, Yang SR, Lam WWM, Wong A, Fan YH, Leung HHW, et al. Risk vs benefit of anti-thrombotic therapy in ischaemic stroke patients with cerebral microbleeds. J Neurol (2008) 255:1679-86. doi:10.1007/s00415-008-0967-7.
31. Charidimou A, Kakar P, Fox Z, Werring DJ. Cerebral microbleeds and recurrent stroke risk: systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. Stroke (2013) 44:995-1001. doi:10.1161/STROKEAHA.111.000038.
32. Longstreth WT, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. Stroke (1996) 27:1274-82. doi:10.1161/01.STR.27.8.1274.
33. Kato H, Izumiyama M, Izumiyama K, Takahashi A, Itoyama Y. Silent cerebral microbleeds on T2*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke (2002) 33:1536-40. doi:10.1161/01.STR.0000018012.65108.86.
34. Naka H, Nomura E, Wakabayashi S, Kajikawa H, Kohriyama T, Mimori Y, et al. Frequency of asymptomatic microbleeds on T2*-weighted MR images of patients with recurrent stroke: association with combination of stroke subtypes and leukoaraiosis. AJNR Am J Neuroradiol (2004) 25:714-9.
35. Gao T, Wang Y, Zhang Z. Silent cerebral microbleeds on susceptibility-weighted imaging of patients with ischemic stroke and leukoaraiosis. Neurol Res (2008) 30:272-6. doi:10.1179/016164107X251556.
36. Pettersen JA, Sathiyamoorthy G, Gao FQ, Szilagyi G, Nadkarni NK, St George-Hyslop P, et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol (2008) 65:790-5. doi:10.1001/archneur.65.6.790.
37. Yamada S, Saiki M, Satow T, Fukuda A, Ito M, Minami S, et al. Periventricular and deep white matter leukoaraiosis have a closer association with cerebral microbleeds than age. Eur J Neurol (2012) 19:98-104. doi:10.1111/j.1468-1331.2011.03451.x.
38. Fisher M. Cerebral microbleeds and white matter disease: separated at birth? Eur J Neurol (2012) 19:2-3. doi:10.1111/j.1468-1331.2011.03466.x.
39. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Neurology (1999) 53:1319-27. doi:10.1212/WNL.53.6.1319.
40. Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology (2002) 59:193-7. doi:10.1212/WNL.59.2.193.
41. Fisher M, Vasilevko V, Cribbs DH. Mixed cerebrovascular disease and the future of stroke prevention. Transl Stroke Res (2012) 3(Suppl 1):39-51. doi:10.1007/s12975-012-0185-6.
42. Chen YW, Gurol ME, Rosand J, Viswanathan A, Rakich SM, Groover TR, et al. Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy. Neurology (2006) 67:83-7. doi:10.1212/01.wnl.0000223613.57229.24.
43. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomised controlled trial. Lancet (2007) 370:493-503. doi:10.1016/S0140-6736(07)61233-1.
44. Eckman MH, Wong LKS, Soo YOY, Lam W, Yang SR, Greenberg SM, et al. Patient-specific decision-making for warfarin therapy in nonvalvular atrial fibrillation: how will screening with genetics and imaging help? Stroke (2008) 39:3308-15. doi:10.1161/STROKEAHA.108.523159.
45. Ahsan SF, Syamal MN, Yaremchuk K, Peterson E, Seidman M. The costs and utility of imaging in evaluating dizzy patients in the emergency room. Laryngoscope (2013) 123:2250-3. doi:10.1002/lary.23798.
46. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care (2004) 10(14 Suppl):S451-8.discussion S458-61,.
47. Mercaldi CJ, Ciarametaro M, Hahn B, Chalissery G, Reynolds MW, Sander SD, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in Medicare beneficiaries with nonvalvular atrial fibrillation. Stroke (2011) 42:112-8. doi:10.1161/STROKEAHA.110.592907.
48. Rosen MP, Oake N, Forster AJ, Goelman A, Levy F. The effect of imaging capacity on the imaging workup of patients with stroke: a preliminary case for a cross-country comparison. J Am Coll Radiol (2011) 8:428-35. doi:10.1016/j.jacr.2011.02.012.
49. Nandigam RN, Viswanathan A, Delgado P, Skehan ME, Smith EE, Rosand J, et al. MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength. AJNR Am J Neuroradiol (2009) 30:338-43. doi:10.3174/ajnr. A1355.
50. Charidimou A, Shakeshaft C, Werring DJ. Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. Front Neurol (2012) 3:133. doi:10.3389/fneur.2012.00133.